title: [Imatinib Combined with VP Low Dose Regiment for Treating Newly Diagnosed Adult Patients with Ph-positive ALL].
abstract: OBJECTIVE
  To investigate the inductive therapeutic effects of imatinib combined with VP low dose regiment on adult patients with Ph-positive acute lymphoblastic leukemia (Ph(+) ALL).
  
  
  METHODS
  Fourteen newly diagnosed adult patients with Ph(+) ALL were treated with VP regimen, and imatinib (400 mg/d) was added at the 8(th) day. VP regimen would be stopped when neutropenia lasted for 1 week or complicated with infection, fever, etc. Therapeutic effects were assessed by bone marrow morphology and quantitative analysis of BCR/ABL:ABL at the 28(th) - 33(rd) day. Patients could be treated with imatinib combined with chemotherapy for consolidation and maintenance therapy or were treated with allogeneic hematopoietic stem cell transplantation after complete remission.
  
  
  RESULTS
  Fourteen cases obtained CR1 after first course of treatment, the median decline of BCR/ABA:ABL was 55.89 (10.25 -180.97) %; during the induction chemotherapy, pulmonary infection occurred in 3 patients, diarrhea in 1 patients, facial edema in 3 patients, however, all these patients were cured after symptomatic treatment, only 1 patient died of relapse after transplantation.
  
  
  CONCLUSIONS
  In the period of tyrosine kinase inhibitor (TKI), inductive chemotherapy combined with imatinib and low dose VP can obtaine satisfactory CR rate and decrease the toxicity of the traditional drugs. It is suggested that TKI combined with VP regimen chemotherapy can achieve CR1 and make possible for allo-HSCT, from which patients can achieve the long-term survival.
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.|Department of Hematology, Affiliated Hospital, Shandong University of Traditional Chinese Medicine, Jinan 250021, Shandong Province, China.
authors.forename: Kui
authors.initials: K
authors.lastname: Liu
authors.affiliation: Department of Internal Medicine, Beijing Puren Hospital, Beijing 100010, China.
authors.forename: Yue-Lu
authors.initials: YL
authors.lastname: Guo
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Zi-Long
authors.initials: ZL
authors.lastname: Yao
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Xiang-Shu
authors.initials: XS
authors.lastname: Jin
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Ran
authors.initials: R
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Xiao-Pin
authors.initials: XP
authors.lastname: Han
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Xiao-Ning
authors.initials: XN
authors.lastname: Gao
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: jingyu301@126.com.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001853:Bone Marrow; D002945:Cisplatin; D016044:Fusion Proteins, bcr-abl; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D060828:Induction Chemotherapy; D009503:Neutropenia; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D047428:Protein Kinase Inhibitors; D012008:Recurrence; D012074:Remission Induction; D014184:Transplantation, Homologous; D014751:Vindesine
chemical_list: D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D002945:Cisplatin; D014751:Vindesine